Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Conditions
- Acinar Cell Adenocarcinoma of the Pancreas
- Duct Cell Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage IV Pancreatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific
Interventions
- DRUG: sorafenib tosylate
- DRUG: everolimus
- OTHER: laboratory biomarker analysis
- OTHER: pharmacogenomic studies
- OTHER: pharmacological study
Sponsor
Roswell Park Cancer Institute
Collaborators